Valuation: Atossa Genetics Inc

Market Cap 26.45M 23.6M 21.94M 19.96M 37.54M 2.5B 38.22M 264M 103M 1.31B 99.24M 97.14M 4.18B P/E 2026 *
-0.71x
P/E 2027 * -0.95x
Enterprise Value 26.45M 23.6M 21.94M 19.96M 37.54M 2.5B 38.22M 264M 103M 1.31B 99.24M 97.14M 4.18B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Genetics Inc

Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2023-12-03
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 68 2014-03-02
Director/Board Member 74 2012-01-31
Change 5-day change 1-year change 3-year change Capi.($)
Average
Weighted average by Cap.

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.5M -29.28M -26.63M -50.11M -3.34B -51.01M -352M -138M -1.74B -132M -130M -5.58B -38.03M -33.94M -31.55M -28.69M -53.98M -3.6B -54.96M -379M -148M -1.88B -143M -140M -6.01B
Net Debt - -
Logo Atossa Genetics Inc
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Genetics Inc